Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1618 1643 1646 1674 4100
This examiner grants 48% of resolved cases
Danaya L. Middleton has 97 resolved cases in Tech Center 1600 and Art Unit 1618. Her allowance rate is 48.5 percent, and the median days to allowance is 1312. The 97 resolved cases provide the data foundation for these performance statistics and the 1312-day median timeline. These figures define the typical experience for applications in her care.
The interview lift of 49.4 percent is a notable metric, as it exceeds the 48.5 percent allowance rate. This figure indicates that an interview provides a substantial increase in the likelihood of an allowance. For the 97 resolved cases, this 49.4 percent lift highlights that direct interaction is an effective way to navigate the 1312-day median path to a patent grant. The 49.4 percent lift is a strategic data point for any practitioner working in Art Unit 1618. Utilizing interviews may significantly alter the prosecution trajectory for applications assigned to this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17383316 | METHOD FOR THE EXPRESSION OF AN ANTIBODY-MULTIMER-FUSION | Non-Final OA | Genentech, Inc. |
| 17642515 | IMMUNOACTIVE MICROPARTICLES AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 17638519 | IMPLANTABLE SCAFFOLDS AND USES THEREOF FOR IMMUNOTHERAPY AND OTHER USES | Final Rejection | The Regents of the University of California |
| 18565306 | NOVEL THERAPEUTIC PEPTIDES FOR NEURODEGENERATION | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18580385 | PROTEASE-MEDIATED TARGET SPECIFIC CYTOKINE DELIVERY USING FUSION POLYPEPTIDE | Non-Final OA | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18023038 | HETERODIMER FC POLYPEPTIDE | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18022342 | HETERODIMER FC POLYPEPTIDE | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18036620 | BIPHASIC SUBCUTANEOUS DOSING REGIMENS FOR ANTI-VLA-4 ANTIBODIES | Final Rejection | BIOGEN MA INC. |
| 17800345 | ANTI- MUC1-SEA ANTIBODIES | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 18327255 | HUMAN ANTIBODIES TO TN ANTIGEN | Final Rejection | Boehringer Ingelheim International GmbH |
| 17425130 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF | Final Rejection | CHILDREN'S NATIONAL MEDICAL CENTER |
| 18287593 | ANTI-TSLP ANTIBODY COMPOSITIONS AND USES THEREOF | Non-Final OA | AMGEN INC. |
| 17770259 | HLA CLASS I SEQUENCE DIVERGENCE AND CANCER THERAPY | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18538932 | SEQUENTIAL TRANSARTERIAL CHEMOEMBOLIZATION, STEREOTACTIC BODY RADIOTHERAPY, AND IMMUNOTHERAPY (START-FIT) FOR HEPATOCELLULAR CARCINOMA | Non-Final OA | The University of Hong Kong |
| 17541627 | ANTI-CD19 COMBINATION THERAPY | Non-Final OA | Incyte Corporation |
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | Final Rejection | Genzyme Corporation |
| 17632181 | TREATMENT OF CANCER WITH A COMBINATION OF AN ANTIBODY THAT BINDS LGR5 AND EGFR AND A TOPOISOMERASE I INHIBITOR | Non-Final OA | Merus N.V. |
| 17925547 | HUMAN IL-15 MUTANT AND USES THEREOF | Final Rejection | Shandong Simcere Biopharmaceutical Co., Ltd. |
| 18004004 | HIGH CONCENTRATION FORMULATION AND USES THEREOF | Non-Final OA | CSL Innovation Pty Ltd. |
| 18013523 | MULTISPECIFIC BINDING PROTEIN OF IMMUNE CELL ENGAGER, PREPARATION THEREFOR AND APPLICATION THEREOF | Final Rejection | NONA BIOSCIENCES (SUZHOU) CO., LTD. |
| 17040109 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | Non-Final OA | UNIVERSITÉ D'AIX MARSEILLE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy